{"id":358264,"date":"2025-08-29T12:04:08","date_gmt":"2025-08-29T12:04:08","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"modified":"2025-08-29T12:04:08","modified_gmt":"2025-08-29T12:04:08","slug":"how-to-buy-kiniksa-pharmaceuticals-international","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","title":{"rendered":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"
text<\/div><\/div>","protected":false},"excerpt":{"rendered":"

text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-358264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Kiniksa Pharmaceuticals (KNSA) hisselerine yat\u0131r\u0131m yapmay\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $33.50, b\u00fcy\u00fcme potansiyeli ve kardiyovask\u00fcler biyoteknoloji f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci.","description_source":{"label":"Description","type":"textarea","formatted_value":"Kiniksa Pharmaceuticals (KNSA) hisselerine yat\u0131r\u0131m yapmay\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $33.50, b\u00fcy\u00fcme potansiyeli ve kardiyovask\u00fcler biyoteknoloji f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci."},"intro":"Kardiyovask\u00fcler t\u0131pta ses getiren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Kiniksa Pharmaceuticals (KNSA), ileri bilim ile etkileyici ticari b\u00fcy\u00fcmeyi birle\u015ftiriyor\u2014yenilik\u00e7i sa\u011fl\u0131k hizmetlerine maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Amiral gemisi ilac\u0131 ARCALYST ile tekrarlayan perikardit tedavisini d\u00f6n\u00fc\u015ft\u00fcren bu \u015firket, kardiyovask\u00fcler terap\u00f6tiklerin gelece\u011fini temsil ediyor. KNSA'n\u0131n neden dikkatinizi hak etti\u011fini ve b\u00fcy\u00fcme hikayelerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kardiyovask\u00fcler t\u0131pta ses getiren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Kiniksa Pharmaceuticals (KNSA), ileri bilim ile etkileyici ticari b\u00fcy\u00fcmeyi birle\u015ftiriyor\u2014yenilik\u00e7i sa\u011fl\u0131k hizmetlerine maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Amiral gemisi ilac\u0131 ARCALYST ile tekrarlayan perikardit tedavisini d\u00f6n\u00fc\u015ft\u00fcren bu \u015firket, kardiyovask\u00fcler terap\u00f6tiklerin gelece\u011fini temsil ediyor. KNSA'n\u0131n neden dikkatinizi hak etti\u011fini ve b\u00fcy\u00fcme hikayelerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"

\ud83d\udcc8 Kiniksa Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/strong><\/p>

29 A\u011fustos 2025 itibar\u0131yla, Kiniksa Pharmaceuticals (KNSA) NASDAQ'ta 33,50 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: 3 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar hisse senedini \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi.<\/p>

Kazan\u00e7 Raporlar\u0131 KNSA Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/p>
Tarih<\/th>Olay<\/th>Haber \u00d6ncesi Fiyat<\/th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead>
29 Tem 2025<\/td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>32,15 $<\/td>%4,2 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td><\/tr>
29 Nis 2025<\/td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>28,40 $<\/td>%8,1 Art\u0131\u015f<\/strong> (rehberlik y\u00fckseltildi)<\/td><\/tr>
25 \u015eub 2025<\/td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>26,80 $<\/td>%6,3 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc g\u00f6r\u00fcn\u00fcm)<\/td><\/tr>
4 Kas 2024<\/td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>24,50 $<\/td>%3,2 D\u00fc\u015f\u00fc\u015f<\/strong> (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td><\/tr>
1 A\u011fu 2024<\/td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>22,75 $<\/td>%7,5 Art\u0131\u015f<\/strong> (s\u00fcrpriz kar)<\/td><\/tr>
2 May 2024<\/td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>20,10 $<\/td>%12,9 Art\u0131\u015f<\/strong> (rehberlik art\u0131\u015f\u0131)<\/td><\/tr> <\/tbody> <\/table>

Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle KNSA'y\u0131 birka\u00e7 g\u00fcn i\u00e7inde %4-8 oran\u0131nda y\u00fckseltir. Temmuz 2025 raporu, ARCALYST gelirlerinin y\u0131ll\u0131k %52 art\u0131\u015fla 156,8 milyon dolara ula\u015fmas\u0131yla hisseyi yeni zirvelere ta\u015f\u0131d\u0131.<\/p>

6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/strong><\/p>

KNSA hisseleri bu d\u00f6nemde etkileyici bir %38,2 getiri<\/strong> sa\u011flad\u0131:<\/p>

  • Mart<\/strong>: 24,20 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li>
  • Nisan<\/strong>: 28,40 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131)<\/li>
  • Haziran<\/strong>: 31,80 $ (rehberlik art\u0131\u015f\u0131 beklentisi)<\/li>
  • Temmuz<\/strong>: 33,65 $ (2. \u00e7eyrek kazan\u00e7lar\u0131nda y\u00fckseli\u015f)<\/li>
  • A\u011fustos<\/strong>: 33,50 $ (mevcut konsolidasyon)<\/li> <\/ul>

    Bu s\u00fcrekli y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p>

    • ARCALYST re\u00e7eteleri 3.475'ten fazla doktora ula\u015ft\u0131<\/li>
    • Pandemi sonras\u0131 kardiyovask\u00fcler ila\u00e7 talebi artt\u0131<\/li>
    • 2. \u00e7eyrekte 17,8 milyon $ net gelirle k\u00e2rl\u0131l\u0131k pozitif hale geldi<\/li> <\/ul>

      \ud83d\udd2e Fiyat Tahmini: 2025-2030<\/strong><\/p>

      • 2025 (Y\u0131l Sonu)<\/strong>: 38-42 $ (ARCALYST b\u00fcy\u00fcmesi ve \u00fcr\u00fcn hatt\u0131 ilerlemesi devam edecek) \u2192 G\u00dc\u00c7L\u00dc AL<\/strong><\/li>
      • 2026<\/strong>: 45-52 $ (KPL-387 Faz 2 verileri ve pazar geni\u015flemesi)<\/li>
      • 2028<\/strong>: 65-80 $ (potansiyel yeni ila\u00e7 onaylar\u0131 ve uluslararas\u0131 b\u00fcy\u00fcme)<\/li>
      • 2030<\/strong>: 100+ $ (kardiyovask\u00fcler franchise hakimiyeti ve \u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131)<\/li> <\/ul>

        Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip etmeli.<\/p>

        \u26a0\ufe0f \u00d6nemli Riskler ve Pozitif Sinyaller<\/strong><\/p>

        Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/p>

        • FDA d\u00fczenleyici engelleri<\/strong>: KPL-387 onay\u0131nda ya\u015fanacak herhangi bir gecikme 2028 projeksiyonlar\u0131n\u0131 etkileyebilir<\/li>
        • Biyoteknoloji volatilitesi<\/strong>: 52 haftal\u0131k aral\u0131k 17,82 $-34,55 $ aras\u0131nda %94 dalgalanma potansiyeli g\u00f6steriyor<\/li>
        • Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer IL-1 inhibit\u00f6rleri geli\u015ftiriyor<\/li>
        • K\u00e2rl\u0131l\u0131k tutarl\u0131l\u0131\u011f\u0131<\/strong>: \u0130yile\u015fiyor olsa da, kazan\u00e7lar Ar-Ge harcamalar\u0131na kar\u015f\u0131 hassamd\u0131r<\/li> <\/ul>

          2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p>

          • Patlay\u0131c\u0131 b\u00fcy\u00fcme<\/strong>: ARCALYST gelir rehberli\u011fi 590-605 milyon dolardan 625-640 milyon dolara y\u00fckseltildi<\/li>
          • \u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: KPL-387 kardiyovask\u00fcler geni\u015fleme i\u00e7in Faz 2\/3 denemelerine giriyor<\/li>
          • Analist g\u00fcveni<\/strong>: 6 \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi, ortalama hedef fiyat 45,17 $ (%35 yukar\u0131 potansiyel)<\/li>
          • Pazar konumu<\/strong>: Tekrarlayan perikardit tedavisinde lider yenilik\u00e7i<\/li> <\/ul>

            \ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/strong><\/p>

            1. K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'ini KNSA'ya ay\u0131r\u0131n\u2014biyoteknoloji dikkatli pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc gerektirir<\/li>
            2. Ortalama maliyetle al\u0131m yap\u0131n<\/strong>: Zamanlama riskini azaltmak i\u00e7in kazan\u00e7 tarihleri civar\u0131nda par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>
            3. Stop-loss belirleyin<\/strong>: Biyoteknoloji volatilitesine kar\u015f\u0131 %15-20 zarar korumas\u0131 sa\u011flay\u0131n<\/li>
            4. 3 Kas\u0131m'\u0131 takip edin<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir<\/li> <\/ol>

              Mizahi yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/em>: \"KNSA gibi biyoteknoloji hisseleriyle i\u015flem yapmak fl\u00f6rt etmek gibidir\u2014bazen peri masal\u0131 sonu ya\u015fars\u0131n\u0131z, bazen FDA taraf\u0131ndan hayaletlenirsiniz. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!\"<\/p>

              \u2705 Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/strong><\/p>
              Ad\u0131m<\/th>\u0130\u015flem<\/th>Neden \u00d6nemli<\/th><\/tr> <\/thead>
              1<\/td>Bir i\u015flem platformu se\u00e7in<\/td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr>
              2<\/td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td><\/tr>
              3<\/td>Fon yat\u0131r\u0131n<\/td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr>
              4<\/td>\"KNSA\" aramas\u0131 yap\u0131n<\/td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr>
              5<\/td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>Limit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmay\u0131 \u00f6nler<\/td><\/tr>
              6<\/td>\u0130nceleyin ve onaylay\u0131n<\/td>Komisyon oranlar\u0131n\u0131 kontrol edin\u2014%1'in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td><\/tr>
              7<\/td>Pozisyonu izleyin<\/td>Kazan\u00e7 tarihleri ve \u00f6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table>

              \ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/strong><\/p>

              Pocket Option biyoteknoloji yat\u0131r\u0131m\u0131 i\u00e7in ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p>

              • Minimum depozito<\/strong>: Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz<\/li>
              • H\u0131zl\u0131 do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC dakikalar i\u00e7inde tamamlan\u0131r<\/li>
              • \u00c7e\u015fitli para \u00e7ekme y\u00f6ntemleri<\/strong>: Kripto, e-c\u00fczdanlar ve banka transferleri dahil 100'den fazla y\u00f6ntem<\/li>
              • Kullan\u0131c\u0131 dostu platform<\/strong>: Karma\u015f\u0131k biyoteknoloji hisselerinde yeni ba\u015flayanlar i\u00e7in ideal<\/li> <\/ul>

                \ud83c\udf0d 2025'te Kiniksa: Kardiyovask\u00fcler \u0130novasyon Lideri<\/strong><\/p>

                Kiniksa Pharmaceuticals, ARCALYST ile tekrarlayan perikardit pazar\u0131nda hakimdir; bu, d\u00fcnya \u00e7ap\u0131nda binlerce ki\u015fiyi etkileyen y\u0131k\u0131c\u0131 bir inflamatuar kalp hastal\u0131\u011f\u0131d\u0131r. Ticari ba\u015far\u0131lar\u0131n\u0131n \u00f6tesinde, kardiyovask\u00fcler inflamasyon tedavisinde devrim yaratabilecek bir sonraki nesil monoklonal antikor KPL-387 \u00fczerinde ilerlemektedirler.<\/p>

                2025 e\u011flenceli bilgi<\/strong>: Kiniksa ara\u015ft\u0131rma ekibi, IL-1 inhibit\u00f6r teknolojilerinin uzun COVID kardiyovask\u00fcler komplikasyonlar\u0131nda da yard\u0131mc\u0131 olabilece\u011fini ke\u015ffetti; bu da milyarlarca dolarl\u0131k devasa yeni bir pazar f\u0131rsat\u0131 a\u00e7\u0131yor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"

                \ud83d\udcc8 Kiniksa Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/strong><\/p>\n

                29 A\u011fustos 2025 itibar\u0131yla, Kiniksa Pharmaceuticals (KNSA) NASDAQ’ta 33,50 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: 3 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar hisse senedini \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi.<\/p>\n

                Kazan\u00e7 Raporlar\u0131 KNSA Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
                Tarih<\/th>\nOlay<\/th>\nHaber \u00d6ncesi Fiyat<\/th>\nHaber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n
                29 Tem 2025<\/td>\n2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n32,15 $<\/td>\n%4,2 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n
                29 Nis 2025<\/td>\n1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n28,40 $<\/td>\n%8,1 Art\u0131\u015f<\/strong> (rehberlik y\u00fckseltildi)<\/td>\n<\/tr>\n
                25 \u015eub 2025<\/td>\nY\u0131ll\u0131k Sonu\u00e7lar<\/td>\n26,80 $<\/td>\n%6,3 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc g\u00f6r\u00fcn\u00fcm)<\/td>\n<\/tr>\n
                4 Kas 2024<\/td>\n3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n24,50 $<\/td>\n%3,2 D\u00fc\u015f\u00fc\u015f<\/strong> (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td>\n<\/tr>\n
                1 A\u011fu 2024<\/td>\n2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n22,75 $<\/td>\n%7,5 Art\u0131\u015f<\/strong> (s\u00fcrpriz kar)<\/td>\n<\/tr>\n
                2 May 2024<\/td>\n1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n20,10 $<\/td>\n%12,9 Art\u0131\u015f<\/strong> (rehberlik art\u0131\u015f\u0131)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle KNSA’y\u0131 birka\u00e7 g\u00fcn i\u00e7inde %4-8 oran\u0131nda y\u00fckseltir. Temmuz 2025 raporu, ARCALYST gelirlerinin y\u0131ll\u0131k %52 art\u0131\u015fla 156,8 milyon dolara ula\u015fmas\u0131yla hisseyi yeni zirvelere ta\u015f\u0131d\u0131.<\/p>\n

                6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/strong><\/p>\n

                KNSA hisseleri bu d\u00f6nemde etkileyici bir %38,2 getiri<\/strong> sa\u011flad\u0131:<\/p>\n

                  \n
                • Mart<\/strong>: 24,20 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li>\n
                • Nisan<\/strong>: 28,40 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131)<\/li>\n
                • Haziran<\/strong>: 31,80 $ (rehberlik art\u0131\u015f\u0131 beklentisi)<\/li>\n
                • Temmuz<\/strong>: 33,65 $ (2. \u00e7eyrek kazan\u00e7lar\u0131nda y\u00fckseli\u015f)<\/li>\n
                • A\u011fustos<\/strong>: 33,50 $ (mevcut konsolidasyon)<\/li>\n<\/ul>\n

                  Bu s\u00fcrekli y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p>\n

                    \n
                  • ARCALYST re\u00e7eteleri 3.475’ten fazla doktora ula\u015ft\u0131<\/li>\n
                  • Pandemi sonras\u0131 kardiyovask\u00fcler ila\u00e7 talebi artt\u0131<\/li>\n
                  • 2. \u00e7eyrekte 17,8 milyon $ net gelirle k\u00e2rl\u0131l\u0131k pozitif hale geldi<\/li>\n<\/ul>\n

                    \ud83d\udd2e Fiyat Tahmini: 2025-2030<\/strong><\/p>\n

                      \n
                    • 2025 (Y\u0131l Sonu)<\/strong>: 38-42 $ (ARCALYST b\u00fcy\u00fcmesi ve \u00fcr\u00fcn hatt\u0131 ilerlemesi devam edecek) \u2192 G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n
                    • 2026<\/strong>: 45-52 $ (KPL-387 Faz 2 verileri ve pazar geni\u015flemesi)<\/li>\n
                    • 2028<\/strong>: 65-80 $ (potansiyel yeni ila\u00e7 onaylar\u0131 ve uluslararas\u0131 b\u00fcy\u00fcme)<\/li>\n
                    • 2030<\/strong>: 100+ $ (kardiyovask\u00fcler franchise hakimiyeti ve \u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131)<\/li>\n<\/ul>\n

                      Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip etmeli.<\/p>\n

                      \u26a0\ufe0f \u00d6nemli Riskler ve Pozitif Sinyaller<\/strong><\/p>\n

                      Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/p>\n

                        \n
                      • FDA d\u00fczenleyici engelleri<\/strong>: KPL-387 onay\u0131nda ya\u015fanacak herhangi bir gecikme 2028 projeksiyonlar\u0131n\u0131 etkileyebilir<\/li>\n
                      • Biyoteknoloji volatilitesi<\/strong>: 52 haftal\u0131k aral\u0131k 17,82 $-34,55 $ aras\u0131nda %94 dalgalanma potansiyeli g\u00f6steriyor<\/li>\n
                      • Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer IL-1 inhibit\u00f6rleri geli\u015ftiriyor<\/li>\n
                      • K\u00e2rl\u0131l\u0131k tutarl\u0131l\u0131\u011f\u0131<\/strong>: \u0130yile\u015fiyor olsa da, kazan\u00e7lar Ar-Ge harcamalar\u0131na kar\u015f\u0131 hassamd\u0131r<\/li>\n<\/ul>\n

                        2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p>\n

                          \n
                        • Patlay\u0131c\u0131 b\u00fcy\u00fcme<\/strong>: ARCALYST gelir rehberli\u011fi 590-605 milyon dolardan 625-640 milyon dolara y\u00fckseltildi<\/li>\n
                        • \u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: KPL-387 kardiyovask\u00fcler geni\u015fleme i\u00e7in Faz 2\/3 denemelerine giriyor<\/li>\n
                        • Analist g\u00fcveni<\/strong>: 6 “G\u00fc\u00e7l\u00fc Al” derecelendirmesi, ortalama hedef fiyat 45,17 $ (%35 yukar\u0131 potansiyel)<\/li>\n
                        • Pazar konumu<\/strong>: Tekrarlayan perikardit tedavisinde lider yenilik\u00e7i<\/li>\n<\/ul>\n

                          \ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/strong><\/p>\n

                            \n
                          1. K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5’ini KNSA’ya ay\u0131r\u0131n\u2014biyoteknoloji dikkatli pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc gerektirir<\/li>\n
                          2. Ortalama maliyetle al\u0131m yap\u0131n<\/strong>: Zamanlama riskini azaltmak i\u00e7in kazan\u00e7 tarihleri civar\u0131nda par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n
                          3. Stop-loss belirleyin<\/strong>: Biyoteknoloji volatilitesine kar\u015f\u0131 %15-20 zarar korumas\u0131 sa\u011flay\u0131n<\/li>\n
                          4. 3 Kas\u0131m’\u0131 takip edin<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir<\/li>\n<\/ol>\n

                            Mizahi yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/em>: “KNSA gibi biyoteknoloji hisseleriyle i\u015flem yapmak fl\u00f6rt etmek gibidir\u2014bazen peri masal\u0131 sonu ya\u015fars\u0131n\u0131z, bazen FDA taraf\u0131ndan hayaletlenirsiniz. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!”<\/p>\n

                            \u2705 Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Ad\u0131m Ad\u0131m<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
                            Ad\u0131m<\/th>\n\u0130\u015flem<\/th>\nNeden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n
                            1<\/td>\nBir i\u015flem platformu se\u00e7in<\/td>\nNASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n
                            2<\/td>\nHesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\nGenellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td>\n<\/tr>\n
                            3<\/td>\nFon yat\u0131r\u0131n<\/td>\nRisk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n
                            4<\/td>\n“KNSA” aramas\u0131 yap\u0131n<\/td>\n\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n
                            5<\/td>\nEmir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\nLimit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmay\u0131 \u00f6nler<\/td>\n<\/tr>\n
                            6<\/td>\n\u0130nceleyin ve onaylay\u0131n<\/td>\nKomisyon oranlar\u0131n\u0131 kontrol edin\u2014%1’in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td>\n<\/tr>\n
                            7<\/td>\nPozisyonu izleyin<\/td>\nKazan\u00e7 tarihleri ve \u00f6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                            \ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/strong><\/p>\n

                            Pocket Option biyoteknoloji yat\u0131r\u0131m\u0131 i\u00e7in ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p>\n

                              \n
                            • Minimum depozito<\/strong>: Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz<\/li>\n
                            • H\u0131zl\u0131 do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC dakikalar i\u00e7inde tamamlan\u0131r<\/li>\n
                            • \u00c7e\u015fitli para \u00e7ekme y\u00f6ntemleri<\/strong>: Kripto, e-c\u00fczdanlar ve banka transferleri dahil 100’den fazla y\u00f6ntem<\/li>\n
                            • Kullan\u0131c\u0131 dostu platform<\/strong>: Karma\u015f\u0131k biyoteknoloji hisselerinde yeni ba\u015flayanlar i\u00e7in ideal<\/li>\n<\/ul>\n

                              \ud83c\udf0d 2025’te Kiniksa: Kardiyovask\u00fcler \u0130novasyon Lideri<\/strong><\/p>\n

                              Kiniksa Pharmaceuticals, ARCALYST ile tekrarlayan perikardit pazar\u0131nda hakimdir; bu, d\u00fcnya \u00e7ap\u0131nda binlerce ki\u015fiyi etkileyen y\u0131k\u0131c\u0131 bir inflamatuar kalp hastal\u0131\u011f\u0131d\u0131r. Ticari ba\u015far\u0131lar\u0131n\u0131n \u00f6tesinde, kardiyovask\u00fcler inflamasyon tedavisinde devrim yaratabilecek bir sonraki nesil monoklonal antikor KPL-387 \u00fczerinde ilerlemektedirler.<\/p>\n

                              2025 e\u011flenceli bilgi<\/strong>: Kiniksa ara\u015ft\u0131rma ekibi, IL-1 inhibit\u00f6r teknolojilerinin uzun COVID kardiyovask\u00fcler komplikasyonlar\u0131nda da yard\u0131mc\u0131 olabilece\u011fini ke\u015ffetti; bu da milyarlarca dolarl\u0131k devasa yeni bir pazar f\u0131rsat\u0131 a\u00e7\u0131yor!<\/p>\n"},"faq":[{"question":"Kiniksa Pharmaceuticals hisseleri nereden al\u0131nabilir?","answer":"Kiniksa hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden KNSA sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Kiniksa'n\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"Kiniksa'n\u0131n amiral gemisi \u00fcr\u00fcn\u00fc ARCALYST, tekrarlayan perikardit tedavisinde kullan\u0131lan yenilik\u00e7i bir ila\u00e7t\u0131r."},{"question":"Kiniksa hisseleri i\u00e7in \u00f6nemli kazan\u00e7 tarihleri nelerdir?","answer":"\u00d6zellikle 3 Kas\u0131m 2025'te a\u00e7\u0131klanacak 3. \u00e7eyrek kazan\u00e7 raporu yat\u0131r\u0131mc\u0131lar i\u00e7in kritik \u00f6neme sahiptir."},{"question":"Kiniksa hisseleri i\u00e7in riskler nelerdir?","answer":"FDA onay s\u00fcre\u00e7lerindeki gecikmeler, biyoteknoloji sekt\u00f6r\u00fcndeki volatilite, rekabet ve k\u00e2rl\u0131l\u0131k dalgalanmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayan biri Kiniksa hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve stop-loss kullanarak dikkatli bir \u015fekilde yat\u0131r\u0131m yapman\u0131z \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Kiniksa Pharmaceuticals hisseleri nereden al\u0131nabilir?","answer":"Kiniksa hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden KNSA sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Kiniksa'n\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"Kiniksa'n\u0131n amiral gemisi \u00fcr\u00fcn\u00fc ARCALYST, tekrarlayan perikardit tedavisinde kullan\u0131lan yenilik\u00e7i bir ila\u00e7t\u0131r."},{"question":"Kiniksa hisseleri i\u00e7in \u00f6nemli kazan\u00e7 tarihleri nelerdir?","answer":"\u00d6zellikle 3 Kas\u0131m 2025'te a\u00e7\u0131klanacak 3. \u00e7eyrek kazan\u00e7 raporu yat\u0131r\u0131mc\u0131lar i\u00e7in kritik \u00f6neme sahiptir."},{"question":"Kiniksa hisseleri i\u00e7in riskler nelerdir?","answer":"FDA onay s\u00fcre\u00e7lerindeki gecikmeler, biyoteknoloji sekt\u00f6r\u00fcndeki volatilite, rekabet ve k\u00e2rl\u0131l\u0131k dalgalanmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayan biri Kiniksa hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve stop-loss kullanarak dikkatli bir \u015fekilde yat\u0131r\u0131m yapman\u0131z \u00f6nerilir."}]}},"yoast_head":"\nKiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T12:04:08+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T12:04:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\",\"name\":\"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-29T12:04:08+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","og_locale":"tr_TR","og_type":"article","og_title":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T12:04:08+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T12:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","name":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-29T12:04:08+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Kiniksa Pharmaceuticals International, plc (KNSA) Hisseleri Nas\u0131l Al\u0131n\u0131r – Kiniksa Pharmaceuticals International, plc (KNSA) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":358270,"slug":"how-to-buy-kiniksa-pharmaceuticals-international","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"pt_AA":{"locale":"pt_AA","id":358267,"slug":"how-to-buy-kiniksa-pharmaceuticals-international","post_title":"Como comprar a\u00e7\u00f5es da Kiniksa Pharmaceuticals International, plc (KNSA) - Investimento em a\u00e7\u00f5es da Kiniksa Pharmaceuticals International, plc (KNSA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=358264"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=358264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=358264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=358264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}